PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film (PREG1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04381728|
Recruitment Status : Completed
First Posted : May 11, 2020
Results First Posted : November 9, 2021
Last Update Posted : November 9, 2021
Intrauterine adhesions (IUA) are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complication and infertility.
Womed Leaf is a medical device specifically designed for intrauterine use that prevents intra-uterine adhesions. It is a film that acts as a mechanical barrier to keep uterus walls separated during healing. It is then naturally discharged through the cervix and vagina in less than 30 days.
The PREG1 clinical investigation is designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy.
|Condition or disease||Intervention/treatment||Phase|
|Intrauterine Adhesion||Device: Womed Leaf||Not Applicable|
Intrauterine adhesions (IUA) are defined as "fibrous strings at opposing walls of the uterus and/or cervix leading to partial or complete obliteration of the cavity". IUAs are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complications and infertility.
Womed Leaf™ is a sterile, degradable polymer film specifically design for intrauterine use. It is inserter in the uterus like an intrauterine device. Once released it will self-deploy into the uterine cavity to form a mechanical barrier keeping uterus walls separated during healing, for several days, thus preventing the formation or recurrence of intrauterine adhesions. It is degraded and discharged naturally through the cervix and vagina in less than 30 days.
The PREG1 clinical investigation is a prospective multicenter, single arm study, designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy in preventing IUA at second look hysteroscopy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film|
|Actual Study Start Date :||November 18, 2019|
|Actual Primary Completion Date :||March 15, 2021|
|Actual Study Completion Date :||March 15, 2021|
Experimental: Womed Leaf
At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.
Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.
A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion.
Device: Womed Leaf
Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
- Safety (Adverse Events) [ Time Frame: 30 days ]The number and severity of polymer film related adverse event
- Efficacy (Rate of Patient With no IUA) [ Time Frame: At second look hysteroscopy between 4 and 8 weeks ]Freedom from intrauterine adhesion
- Efficacy (Intrauterine Adhesion Severity According to AFS Classification) [ Time Frame: At second look hysteroscopy between 4 and 8 weeks ]
Severity of IUAs according to American Fertility Society (AFS) classification systems of adhesions.
Pronostic classification => Hysteroscopy score Stade I (mild) => 1-4 Stade II (moderate) => 5-8 Stade III (severe) => 9-12
- Efficacy (Intrauterine Adhesion Severity According to ESGE Classification) [ Time Frame: At second look hysteroscopy between 4 and 8 weeks ]
Severity of IUAs according to European Society of Gynecological Endoscopy (ESGE) classification systems of adhesions.
I => Thin or filmy IUA easily ruptured by HSC sheath alone. Cornual areas normal II => Singular dense IUA connecting separate parts of the uterine cavity. Visualization of both tubal ostia possible. Cannot be ruptured by HSC sheath alone IIa => Occluding IUA only in the region of the internal cervical os. Upper uterine cavity normal III => Multiple dense IUA connecting separate parts of the uterine cavity. Unilateral obliteration of ostial areas of the tubes IV => Extensive dense IUA with (partial) occlusion of the uterine cavity. Both tubal ostial areas (partially) occluded Va => Extensive endometrial scarring and fibrosis in combination with grade I or grade II IUA with amenorrhea or pronounced hypomenorrhea Vb => Extensive endometrial scarring and fibrosis in combination with grade III or grade IV IUA with amenorrhea
- Adverse Events [ Time Frame: 30 days ]Number of adverse events (AE) at 30 days
- Device Technical Success [ Time Frame: During operation: T=0 ]Defined as the rate of success of the following 2 steps : insertion and release
- Womed Leaf Residuals [ Time Frame: At second look hysteroscopy: 4-8 weeks ]Presence of Womed Leaf residuals in the uterus
- Womed Leaf Discharge Feedback : Time Interval in Days Between Surgery and Discharge [ Time Frame: At second look hysteroscopy: 4-8 weeks ]Uterine film discharge experience as recalled by subject using a survey to be asked to the patient
- Device Manipulation [ Time Frame: During intervention: T=0 ]Device manipulation duration from insertion to withdrawal.
- Womed Leaf Discharge Feedback Questionnaire (Polymer Tolerance Assessed on a Scale From 1 (no Discomfort) to 10 (Extremely Disturbing)) [ Time Frame: At second look hysteroscopy: 4-8 weeks ]Uterine film discharge experience as recalled by subject using a survey to be asked to the patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04381728
|CHU Bicêtre (APHP)|
|Zaans Medical Center|